A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

• Male or female subjects aged greater than or equal to (\>=) 18 years

• With Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry

• At least 1 measurable tumor lesion

• With histologically confirmed metastatic or recurrent (Stage IV) non-small cell lung cancer (NSCLC)

• With availability of a recently-obtained, formalin-fixed, paraffin-embedded (FFPE) tissue sample containing tumor (biopsy from a non-irradiated area preferably within 6 months) or a minimum number of 10 (preferably 25) unstained tumor slides cut within 1 week, and suitable for PD-L1 expression assessment

• Subjects must not have received any treatment for systemic lung cancer, and have an estimated life expectancy of more than 12 weeks

• Other protocol defined criteria could apply